Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review
Anticoagulant therapy for atrial fibrillation (AF) plays an important role in preventing thromboembolic events. This review discusses anticoagulant therapy in patients with AF and chronic anemia of varying severity. The search was carried out in PubMed and Library electronic databases from 2010 to 2...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Concilium Medicum
2024-12-01
|
| Series: | КардиоСоматика |
| Subjects: | |
| Online Access: | https://cardiosomatics.ru/2221-7185/article/viewFile/635908/pdf_1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823858065887199232 |
|---|---|
| author | Tatyana S. Degtyareva Kristina G. Pereverzeva Sergey S. Yakushin Natalia N. Peregudova |
| author_facet | Tatyana S. Degtyareva Kristina G. Pereverzeva Sergey S. Yakushin Natalia N. Peregudova |
| author_sort | Tatyana S. Degtyareva |
| collection | DOAJ |
| description | Anticoagulant therapy for atrial fibrillation (AF) plays an important role in preventing thromboembolic events. This review discusses anticoagulant therapy in patients with AF and chronic anemia of varying severity. The search was carried out in PubMed and Library electronic databases from 2010 to 2023. Based on the analysis of full text literature, the authors concluded that currently oral anticoagulants in patients with AF and mild chronic anemia (Hb 90 g/L) and, according to some studies, in patients with moderate anemia (Hb 80 g/L) are considered reasonable. Patients with AF and moderate anemia (Hb 71–80 g/L) require an individualized approach to therapy with oral anticoagulants, since its benefit is not obvious in this subgroup, and the risk of hemorrhagic complications is high. Currently, severe anemia is a contraindication to oral anticoagulants in patients with AF. |
| format | Article |
| id | doaj-art-9a4d718d5eec437f8ad1f7a5c05f9b3b |
| institution | Kabale University |
| issn | 2221-7185 2658-5707 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Concilium Medicum |
| record_format | Article |
| series | КардиоСоматика |
| spelling | doaj-art-9a4d718d5eec437f8ad1f7a5c05f9b3b2025-02-11T15:00:52ZengConcilium MedicumКардиоСоматика2221-71852658-57072024-12-0115436537410.17816/CS63590876587Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative reviewTatyana S. Degtyareva0https://orcid.org/0009-0004-9465-1441Kristina G. Pereverzeva1https://orcid.org/0000-0001-6141-8994Sergey S. Yakushin2https://orcid.org/0000-0002-1394-3791Natalia N. Peregudova3https://orcid.org/0000-0001-6177-1405Ryazan State Medical UniversityRyazan State Medical UniversityRyazan State Medical UniversityRyazan State Medical UniversityAnticoagulant therapy for atrial fibrillation (AF) plays an important role in preventing thromboembolic events. This review discusses anticoagulant therapy in patients with AF and chronic anemia of varying severity. The search was carried out in PubMed and Library electronic databases from 2010 to 2023. Based on the analysis of full text literature, the authors concluded that currently oral anticoagulants in patients with AF and mild chronic anemia (Hb 90 g/L) and, according to some studies, in patients with moderate anemia (Hb 80 g/L) are considered reasonable. Patients with AF and moderate anemia (Hb 71–80 g/L) require an individualized approach to therapy with oral anticoagulants, since its benefit is not obvious in this subgroup, and the risk of hemorrhagic complications is high. Currently, severe anemia is a contraindication to oral anticoagulants in patients with AF.https://cardiosomatics.ru/2221-7185/article/viewFile/635908/pdf_1anemiaatrial fibrillationoral anticoagulant therapyapixabandabigatran etexilaterivaroxabanedoxabanoral anticoagulants |
| spellingShingle | Tatyana S. Degtyareva Kristina G. Pereverzeva Sergey S. Yakushin Natalia N. Peregudova Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review КардиоСоматика anemia atrial fibrillation oral anticoagulant therapy apixaban dabigatran etexilate rivaroxaban edoxaban oral anticoagulants |
| title | Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review |
| title_full | Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review |
| title_fullStr | Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review |
| title_full_unstemmed | Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review |
| title_short | Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review |
| title_sort | prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia a narrative review |
| topic | anemia atrial fibrillation oral anticoagulant therapy apixaban dabigatran etexilate rivaroxaban edoxaban oral anticoagulants |
| url | https://cardiosomatics.ru/2221-7185/article/viewFile/635908/pdf_1 |
| work_keys_str_mv | AT tatyanasdegtyareva prospectsoforalanticoagulanttherapyinpatientswithatrialfibrillationandchronicanemiaanarrativereview AT kristinagpereverzeva prospectsoforalanticoagulanttherapyinpatientswithatrialfibrillationandchronicanemiaanarrativereview AT sergeysyakushin prospectsoforalanticoagulanttherapyinpatientswithatrialfibrillationandchronicanemiaanarrativereview AT natalianperegudova prospectsoforalanticoagulanttherapyinpatientswithatrialfibrillationandchronicanemiaanarrativereview |